So, the semaglutide ... why I continue to cover Novo Nordisk with a "Strong Buy" rating despite the increased competition from Eli Lilly and Trump's attempts to lower drug prices.

With a U.S. Food and Drug Administration ban on copycat semaglutide drugs now in effect, Novo Nordisk is launching a series of initiatives to improve access to authentic versions of its ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Novo Nordisk is banking on fresh leadership ... closer to entering the market. Unlike oral semaglutide, Eli Lilly's pill is a small-molecule drug and not a peptide medication.

FRANKFURT, Germany — (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy ... on the same basic ingredient, semaglutide. At the peak, the ...